Belgium-Based Cardio3 BioSciences To Open Facility In Rochester, Minnesota
03/03/2015
The company said it will hire 33 people to work at a 15,000-square-foot facility in the Minnesota BioBusiness Center in downtown Rochester. The company plans to further develop its C-Cure pharmaceutical therapy at the center.
As an incentive, the Minnesota Department of Employment and Economic Development will award the company $357,000 from the Minnesota Job Creation Fund once Cardio3 completes its investment and hiring goals.
“Cardio3 is a global company with groundbreaking heart therapy treatments and is a welcome addition to Minnesota’s world-leading destination for life sciences,” said DEED Commissioner Katie Clark Sieben. “The company’s choice to invest in Minnesota will mean positive economic benefits for the community, including new, high-quality jobs and an increase in the local tax base.”
Cardio3 BioSciences, headquartered in Mont-Saint-Guibert, Belgium, was founded in 2007 with a focus on discovering, developing and commercializing regenerative and protective therapies for cardiovascular diseases. The company’s C-Cure therapy works by harvesting a patient’s cells from bone marrow and reprogramming them to repair that patient’s damaged heart muscles.
The Mayo Clinic, which has been working with Cardio3 for several years to develop the therapy, has a small ownership stake in the company.
“This project was seven years in the making,” said Rochester Mayor Ardell Brede. “It's gratifying to see the hard work put into our annual BIO International trade show attendance pay off. Cardio3 will be a great addition to our business community.”
Project Announcements
AMI Metals Expands Spokane, Washington, Production Operations
06/20/2025
Newly Weds Foods Plans Dyersburg, Tennessee, Production Operations
06/20/2025
Yaskawa American Expands Franklin, Wisconsin, Headquarters Operations
06/19/2025
Cayuga Milk Ingredients Expands Cayuga County, New York, Production Operations
06/19/2025
Gap Upgrades Gallatin, Tennessee, Logistics Operations
06/19/2025
Swiss-Based Galderma Plans Miami, Florida, Headquarters Operations
06/19/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
The New Math Behind Mexico and U.S. Manufacturing Decisions
Q2 2025